Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
11,749
datasets available to search
ShareScore release 0.9.0
Dataset results
11,749 results for “patient safety”
Data from: Safety and efficacy of dual antiplatelet pretreatment in ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis
Objective: Conflicting data exist regarding the safety and efficacy of IV thrombolysis (IVT) in acute ischemic stroke (AIS) patients receiving dual antiplatelet pretreatment (DAPP). The aim of the present systematic review and meta-analysis is to assess the safety and outcome of DAPP history among AIS patients treated with IVT. Methods: We performed a comprehensive literature review to identify studies that investigated the safety and efficacy of DAPP among AIS patients treated with IVT. Results: We identified 9 studies comprising 66,675 patients. In unadjusted analyses, DAPP was associated with higher likelihood of pooled symptomatic intracranial hemorrhage (sICH, OR = 2.26, 95% CI 1.39–3.67) and 3-month mortality (OR = 1.47, 95% CI 1.27–1.73). DAPP was also related to higher odds of sICH according to SITS-MOST (OR = 2.71, 95% CI 2.05–3.59), ECASS II (OR=2.23, 95% CI 1.46–3.40) and NINDS (OR=1.59, 95% CI 1.38–1.83) definitions. There was no association between DAPP and 3-month favorable functional outcome (FFO, mRS 0-1), and 3-month functional independence (FI, mRS 0-2). In adjusted analyses, history of DAPP was not associated with pooled sICH (OR=2.03, 95% CI 0.75–5.25), 3-month mortality (OR=1.11, 95% CI 0.87–1.40), 3-month FFO (OR=0.92, 95% CI 0.77–1.09), and 3-month FI (OR=1.01, 95% CI 0.89–1.15). Conclusions: After adjustment for potential confounders DAPP appears not to be associated with higher risk of adverse outcomes in AIS patients treated with IVT.
Supplemental material for: PROMISE-2: Efficacy and safety of eptinezumab in patients with chronic migraine
Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). Methods: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1–12. Results: Among treated participants (n = 1072), baseline mean MMDs was ~16.1 across groups. Treatment with eptinezumab 100 mg and 300 mg was associated with significant reductions in MMDs across weeks 1–12 compared with placebo (placebo, −5.6, 100 mg, −7.7, p < 0.0001 vs placebo; 300 mg, −8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab treated patients at an incidence of greater than 2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). Conclusion: In patients with CM, eptinezumab 100 mg and 300 mg was associated with a significant reduction in MMDs from the day following IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.
Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes
ClinicalTrials.gov study NCT05933174. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
ClinicalTrials.gov study NCT02204397. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation
ClinicalTrials.gov study NCT03620760. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
ClinicalTrials.gov study NCT05699486. IPD Sharing: NO. Countries: 1. Publications: 0.
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
ClinicalTrials.gov study NCT06798454. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)
ClinicalTrials.gov study NCT06594094. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluation of Performances and Safety of the Medical Device Blueback® Physio for Patients With Chronic Low Back Pain
ClinicalTrials.gov study NCT04592094. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.
ClinicalTrials.gov study NCT00181545. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
ClinicalTrials.gov study NCT04161430. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Tolerability of VGB-R04 in Patients With Haemophilia B
ClinicalTrials.gov study NCT05152732. IPD Sharing: YES. Countries: 1. Publications: 0.
Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients
ClinicalTrials.gov study NCT04480398. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR
ClinicalTrials.gov study NCT07159087. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
ClinicalTrials.gov study NCT01654484. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT04893148. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Effectiveness of Left Bundle Branch Pacing in Patients With Cardiac Dysfunction and AV Block
ClinicalTrials.gov study NCT05553626. IPD Sharing: NO. Countries: 1. Publications: 0.
A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients
ClinicalTrials.gov study NCT01567540. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT05142189. IPD Sharing: NO. Countries: 8. Publications: 0.
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
ClinicalTrials.gov study NCT00390650. IPD Sharing: Not stated. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.